Eletriptan provides consistent migraine relief: results of a within-patient multiple-dose study

  • M Almas
  • S Tepper
  • S Landy
  • E Ramos
Open Access
Poster presentation


Placebo Migraine Migraine Attack Eletriptan Migraine Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


To evaluate the consistency of response to eletriptan in migraine.


Surveys indicate that more than 40% of individuals have an average headache frequency of 2 or more attacks per month. Lack of consistent response has been cited in patient surveys as one of the top 3 reasons for dissatisfaction with migraine treatments.


Patients first completed an open-label, lead-in period in which they treated 3 migraine attacks with eletriptan 40 mg. Based on response to open-label treatment, patients were treated with either eletriptan 40 mg (E40; N=539) or eletriptan 80 mg (E80; N=432) in a 4-attack consistency of response study in which placebo was substituted, in a randomized, double-blind fashion, for the treatment of one attack. Headache response was defined as improvement at 2 hours post-dose to a headache intensity of none (pain-free) or mild. Within-patient consistency was defined a priori as headache response at 2 hours on at least 2 out of 3 attacks.


During double-blind treatment, within-patient consistency was 77% for E40 and 73% for E80. For patients (N=47) who had responded to 0/3 attacks on E40 in the open-label phase, titration to the E80 dose resulted in headache response in 55%. A repeated measures logistic regression analysis found that sustained headache response at 24 hours, averaged across 3 attacks, was significantly higher on both E40 vs. placebo (49% vs. 32%; p < 0.001) and E80 vs. placebo (43% vs. 11%; p < 0.001). Sustained pain-free at 24 hours, averaged across all 3 attacks, was also significantly higher on both E40 vs. placebo (30% vs. 5%; p < 0.001) and E80 vs. placebo (25% vs. 3%; p < 0.001).


Eletriptan showed consistent and sustained efficacy in the treatment of migraine. Funded by Pfizer Inc.

Copyright information

© Almas et al; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • M Almas
    • 1
  • S Tepper
    • 2
  • S Landy
    • 3
  • E Ramos
    • 1
  1. 1.Pfizer IncUSA
  2. 2.Cleveland ClinicUSA
  3. 3.Wesley Neurology and Headache ClinicUSA

Personalised recommendations